On March 12, 2024 Pearl Bio (a synthetic biology company backed by Khosla Ventures) reported that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids (Press release, Pearl Bio, MAR 12, 2024, View Source [SID1234641089]). Bolstering this collaboration is the deep expertise and patent portfolio licensed from the labs of scientific co-founders, Farren Isaacs (Yale) and Michael Jewett (Stanford) for using Genomically Recoded Organisms (GROs) to encode synthetic chemistries, paving the road for entirely new classes of multi-functionalized biologics with tunable properties.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Pearl team is excited to leverage our blocking IP on genome recoding and translation engineering to advance novel biologics with synthetic amino acids in partnership with Merck.
The collaboration will initially focus on discovery and development of biologic therapies for the treatment of cancer leveraging Pearl’s exclusive GRO technology, unique ability to work in both cell-based and cell-free systems and proprietary tethered ribosomes to encode synthetic monomers and target previously inaccessible epitopes.
"We are excited to demonstrate the power of Pearl’s technology in our partnership with Merck to create multi-functionalized therapeutic candidates with tunable properties solving for some of the key shortcomings confronting biologics," explained Co-Founder and President, Amy Cayne Schwartz.
Under the agreement, Pearl is eligible to receive payments totaling up to $1B across upfront, option and milestone payments in addition to potential royalties on sales of approved products derived from the collaboration.
"Merck is excited to collaborate with Pearl, a pioneer in developing recoded organisms, to produce novel biologics enabled by synthetic chemistries," shared Juan Alvarez, Vice President of Discovery Biologics at Merck Research Laboratories.